The influence of different types of SARS-CoV-2 within the immunogenicity of patients who are immunocompromised is another potential point of interest. 2.30 to 0.49) than healthy individuals in AU/ml. Stratified analyses were conducted further relating to numerous potential factors in full-text studies. == Summary == Individuals who are immunocompromised and received more vaccines shown poorer humoral reactions and seropositive incidence after SARS-CoV-2 vaccination than healthy individuals. Despite the lack of observable favor for individuals with autoimmune diseases, the tendency of performance of SARS-CoV-2 vaccines is definitely close to that for healthy populations. Individuals who are immunocompromised should be provided a better SARS-CoV-2 vaccination routine, considering numerous vaccine subtypes, dose(s), variants of concern, and immunoassays. Keywords:Autoimmune disease, immunogenicity, SARS-CoV-2 vaccines, meta-analysis == Intro == Vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed during the emergence of SARS-CoV-2, and various vaccine types and subtypes had been produced in such short period as well [1]. Mainstream vaccine types including messenger RNA (mRNA) platforms, adenoviral vectors, and inactivated disease ZXH-3-26 vaccines have been vaccinated in many countries and towns [2]. The common promotion of vaccine platforms significantly bolstered general public confidence in acquiring immunological safety amid viral spread. However, vaccines have indefinite effectiveness and security in among large and complex populations worldwide, such as healthy populations and individuals who are immunocompromised. One study offers emphasized that type and composition of mRNA formulation was linked to difference ZXH-3-26 between security of BNT162b2 and mRNA-1273 vaccines [3]. Haidar et al. [4] PCDH12 have reported higher antibody level in individuals with hematologic malignancy who received mRNA-1273 than those who received BNT162b2 after the third dose. Additionally, another study offers indicated that individuals who are immunocompromised do not show a striking pattern of increase in immunogenicity following mRNA vaccine compared to healthy population [5]. Moreover, inactivated vaccines have a certain probability of exerting harmful effects in individuals rather than providing safety from the disease [6]. Thus, this can lead to the hypothesis that unique vaccine types and combination protocol individuals applied could be potentially shaped the strong or weak immune response after immunizations. Consequently, the influence of various vaccine types on individuals with autoimmune diseases including homologous and heterogeneous vaccine plan needs to become explored. For individuals who are immunocompromised, no unified definition scope exists. Moreover, unpredicted SARS-CoV-2 variants of concern might threaten the immunity of individuals who are immunocompromised [7,8]. Since individuals with autoimmune diseases take immunosuppressive medicines and receive biological therapy, referring to multiple administrations of treatments (e.g. anti-tumor necrosis element (TNF), methotrexate, ustekinumab, secukinumab, and prednisone) with different diseases associated with effectiveness of SARS-CoV-2 vaccines [8]. Several studies possess reported within the substantial variations in the performance between variants and proved that vaccine recipients have decreased performance during emergence of the Delta variant, such as the B.1.617.2 variant ZXH-3-26 [9,10]. The influence of different types of SARS-CoV-2 within the immunogenicity of individuals who are immunocompromised is definitely another potential point of interest. Overall, numerous strategies concerning SARS-CoV-2 vaccination have been proposed, and whether numerous effectiveness of SARS-CoV-2 vaccines types, vaccine doses (first dose, second dose, third dose and even forth dose), history of earlier SARS-CoV-2 illness, SARS-CoV-2 variants of concerns, utilized immunoassay, administration of immunosuppression treatments, and different kind of autoimmune disease individuals diagnosed could possibly impact humoral response among those individuals with autoimmune diseases is controversial. Although several earlier meta-analyses and systematic reviews have exposed that some individuals with autoimmune inflammatory diseases (AIDs) receive more benefits of SARS-CoV-2 vaccines than harmful effects, adequate data on these individuals will also be lacking [1113]. A recent retrospective study [14] offers highlighted that not all folks who are immunocompromised have strong serological reactions after receiving mRNA vaccines following a third dose with 6 months of follow-up. However, no comprehensive and acquired meta-analysis was published on autoimmune disease (such as AIDs, immune mediated inflammatory diseases [IMIDs],.